clinical trial · NCT07227818
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
SchizophreniaNBI-1117568Placebo
brief summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
started
Dec 16, 2025
primary completion
Jul 1, 2029
completion
Jul 1, 2029
last updated
Apr 15, 2026
official title
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol